208 related articles for article (PubMed ID: 9625639)
21. Modern treatment to reduce pulmonary arterial pressure in pulmonary arterial hypertension.
Akagi S; Matsubara H; Nakamura K; Ito H
J Cardiol; 2018 Dec; 72(6):466-472. PubMed ID: 29898864
[TBL] [Abstract][Full Text] [Related]
22. Successful transition from intravenous to inhaled prostacyclin in a patient with pulmonary hypertension and right ventricular failure.
Reddy MT; Patel H; Ventura HO
Congest Heart Fail; 2008; 14(5):285-6. PubMed ID: 18983294
[No Abstract] [Full Text] [Related]
23. Recurrent portopulmonary hypertension after liver transplantation: management with epoprostenol and resolution after retransplantation.
Kett DH; Acosta RC; Campos MA; Rodriguez MJ; Quartin AA; Schein RM
Liver Transpl; 2001 Jul; 7(7):645-8. PubMed ID: 11460234
[TBL] [Abstract][Full Text] [Related]
24. High levels of nitric oxide in individuals with pulmonary hypertension receiving epoprostenol therapy.
Ozkan M; Dweik RA; Laskowski D; Arroliga AC; Erzurum SC
Lung; 2001; 179(4):233-43. PubMed ID: 11891614
[TBL] [Abstract][Full Text] [Related]
25. Medical & surgical approaches to pulmonary hypertension.
McLaughlin VV; Rich S
Compr Ther; 1997 Sep; 23(9):612-6. PubMed ID: 9285162
[TBL] [Abstract][Full Text] [Related]
26. Twin pregnancy in a woman on long-term epoprostenol therapy for primary pulmonary hypertension. A case report.
Badalian SS; Silverman RK; Aubry RH; Longo J
J Reprod Med; 2000 Feb; 45(2):149-52. PubMed ID: 10710749
[TBL] [Abstract][Full Text] [Related]
27. [Inhaled prostacyclin and iloprost in severe pulmonary hypertension secondary to pulmonary fibrosis].
Olschewski H; Ghofrani HA; Walmrath D; Schermuly R; Temmesfeld-Wollbrück B; Grimminger F; Seeger W
Pneumologie; 2000 Mar; 54(3):133-42. PubMed ID: 10783653
[TBL] [Abstract][Full Text] [Related]
28. Use of epoprostenol (Flolan) in the management of primary pulmonary hypertension.
Kayser SR
Prog Cardiovasc Nurs; 1998; 13(3):39-41, 45. PubMed ID: 9950022
[No Abstract] [Full Text] [Related]
29. Continuous intravenous prostacyclin for advanced primary pulmonary hypertension.
Archer-Chicko C
Dimens Crit Care Nurs; 2000; 19(2):14-21. PubMed ID: 10876492
[TBL] [Abstract][Full Text] [Related]
30. Moderate-term effect of epoprostenol on severe portopulmonary hypertension.
Kato H; Katori T; Nakamura Y; Kawarasaki H
Pediatr Cardiol; 2003; 24(1):50-3. PubMed ID: 12574979
[TBL] [Abstract][Full Text] [Related]
31. Nebulized prostacyclin for pulmonary hypertension: a step in the right direction.
Wang A; Bashore TM
Eur Heart J; 1997 Sep; 18(9):1364-5. PubMed ID: 9458437
[No Abstract] [Full Text] [Related]
32. [Effects of long-term treatment with prostacyclin on plasma adrenomedullin in patients with primary pulmonary hypertension].
Nakayama T; Ishikita T; Matsuura H; Saji T
J Cardiol; 2001 Nov; 38(5):263-71. PubMed ID: 11729726
[TBL] [Abstract][Full Text] [Related]
33. Pulmonary edema during acute infusion of epoprostenol in a patient with pulmonary hypertension and limited scleroderma.
Farber HW; Graven KK; Kokolski G; Korn JH
J Rheumatol; 1999 May; 26(5):1195-6. PubMed ID: 10332990
[TBL] [Abstract][Full Text] [Related]
34. Advances in prostacyclin therapy for pulmonary arterial hypertension.
Eells PL
Crit Care Nurse; 2004 Apr; 24(2):42-8, 50-4. PubMed ID: 15098310
[No Abstract] [Full Text] [Related]
35. Epoprostenol and pulmonary arterial hypertension: 20 years of clinical experience.
Sitbon O; Vonk Noordegraaf A
Eur Respir Rev; 2017 Jan; 26(143):. PubMed ID: 28096285
[TBL] [Abstract][Full Text] [Related]
36. The acute hemodynamic effect of IV nitroglycerin and dipyridamole in patients with pulmonary arterial hypertension: comparison with IV epoprostenol.
Sulica R; Dinh HV; Dunsky K; Fuster V; Poon M
Congest Heart Fail; 2005; 11(3):139-44; quiz 145-6. PubMed ID: 15947535
[TBL] [Abstract][Full Text] [Related]
37. Improvement in pulmonary hemodynamics during intravenous epoprostenol (prostacyclin): A study of 15 patients with moderate to severe portopulmonary hypertension.
Krowka MJ; Frantz RP; McGoon MD; Severson C; Plevak DJ; Wiesner RH
Hepatology; 1999 Sep; 30(3):641-8. PubMed ID: 10462369
[TBL] [Abstract][Full Text] [Related]
38. Long-term follow-up of portopulmonary hypertension: effect of treatment with epoprostenol.
Fix OK; Bass NM; De Marco T; Merriman RB
Liver Transpl; 2007 Jun; 13(6):875-85. PubMed ID: 17539008
[TBL] [Abstract][Full Text] [Related]
39. Effects of long-term infusion of prostacyclin (epoprostenol) on echocardiographic measures of right ventricular structure and function in primary pulmonary hypertension. Primary Pulmonary Hypertension Study Group.
Hinderliter AL; Willis PW; Barst RJ; Rich S; Rubin LJ; Badesch DB; Groves BM; McGoon MD; Tapson VF; Bourge RC; Brundage BH; Koerner SK; Langleben D; Keller CA; Murali S; Uretsky BF; Koch G; Li S; Clayton LM; Jöbsis MM; Blackburn SD; Crow JW; Long WA
Circulation; 1997 Mar; 95(6):1479-86. PubMed ID: 9118516
[TBL] [Abstract][Full Text] [Related]
40. Treprostinil inhibits the recruitment of bone marrow-derived circulating fibrocytes in chronic hypoxic pulmonary hypertension.
Nikam VS; Schermuly RT; Dumitrascu R; Weissmann N; Kwapiszewska G; Morrell N; Klepetko W; Fink L; Seeger W; Voswinckel R
Eur Respir J; 2010 Dec; 36(6):1302-14. PubMed ID: 20525716
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
